BackBellicum Pharmaceuticals Overview

Bellicum Pharmaceuticals Current Cash

Track Bellicum Pharmaceuticals's current cash ($5.9M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$5.91M
79.45% YoYΔ $-22.85M vs prior year quarter

Peer trimmed avg / median

Loading

Bellicum Pharmaceuticals Current Cash History

Loading

Bellicum Pharmaceuticals vs. peers: Current Cash Comparison

Loading

Bellicum Pharmaceuticals Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bellicum Pharmaceuticals (BLCM) FAQ

The latest current cash for BLCM is $5.9M as of September 2023. That compares with $29M in the prior-year period — down 79.5% year over year. Investors often review this figure alongside Bellicum Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, BLCM's current cash moved from $29M to $5.9M — a 79.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bellicum Pharmaceuticals's operating scale or balance-sheet position.

A current cash figure of $5.9M for BLCM is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BLCM's current cash ($5.9M), review year-over-year change from $29M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Bellicum Pharmaceuticals's current cash against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.